Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
IPO Year: 2014
Exchange: NASDAQ
Website: intersectent.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2021 | $28.25 | Outperform → Market Perform | SVB Leerink |
| 8/10/2021 | Buy → Neutral | BTIG | |
| 8/9/2021 | $29.00 → $28.25 | Buy → Hold | Canaccord Genuity |
| 8/9/2021 | $28.25 | Buy → Neutral | Guggenheim |
| 6/24/2021 | $21.00 → $23.00 | Market Perform → Outperform | SVB Leerink |
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
Submission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
4 - Intersect ENT, Inc. (0001271214) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
SVB Leerink downgraded Intersect ENT from Outperform to Market Perform and set a new price target of $28.25
BTIG downgraded Intersect ENT from Buy to Neutral
Canaccord Genuity downgraded Intersect ENT from Buy to Hold and set a new price target of $28.25 from $29.00 previously
Guggenheim downgraded Intersect ENT from Buy to Neutral and set a new price target of $28.25
SVB Leerink upgraded Intersect ENT from Market Perform to Outperform and set a new price target of $23.00 from $21.00 previously
SVB Leerink reiterated coverage of Intersect ENT with a rating of Market Perform and set a new price target of $21.00 from $23.00 previously
SVB Leerink reiterated coverage of Intersect ENT with a rating of Market Perform and set a new price target of $25.00 from $24.00 previously
SVB Leerink reiterated coverage of Intersect ENT with a rating of Market Perform and set a new price target of $25.00 from $24.00 previously
POSASR - Intersect ENT, Inc. (0001271214) (Filer)
RW WD - Intersect ENT, Inc. (0001271214) (Filer)
15-12B - Intersect ENT, Inc. (0001271214) (Filer)
S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
EFFECT - Intersect ENT, Inc. (0001271214) (Filer)
RW - Intersect ENT, Inc. (0001271214) (Filer)
POS AM - Intersect ENT, Inc. (0001271214) (Filer)
S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
S-8 POS - Intersect ENT, Inc. (0001271214) (Filer)
Fastest customizable press release news feed in the world
Current President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the
Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist, ER/urgent care and outpatient visits, as well as sinus-related endoscopies Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp
Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company's PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic sinus surgery (FESS). FESS is used to treat chronic rhinosinusitis, a persistent inflammation of the sinuses that can be debilitating to patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005307/en/PROPEL Contour® (Photo: Business Wire) Intersect ENT's P
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm
DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ:XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose,
VenSure and Cube Join the Company's Portfolio of Localized Drug Delivery Creating an Integrated Offering of ENT Technologies to Treat CRS Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the U.S. nationwide commercial availability of the VenSure™ Balloon Sinus Dilation System and Cube™4D Navigation System with VirtuEye™ photo registration. The VenSure Balloon and Cube 4D Navigation Systems are used in procedures that are designed to improve debilitating chronic rhinosinusitis (CRS) symptoms. VirtuEye photo registration is an exclusive and novel, touchless technology that allows for ea
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update. Second Quarter 2021 Overview Preliminary and unaudited revenue of approximately $27.3 million. Record quarterly SINUVA revenue of approximately $2.7 million. Cash, cash equivalents, restricted cash, and short-term investments of approximately $76.2 million as of June 30, 2021. Company reiterates full year 2021 revenue guidance of $117 million - $121 million "As the broader economy opens up, our preliminary second quarter results reflect strong sequential pe
Live Leadership Updates
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers
Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005421/en/Mark L. Alley (Photo: Business Wire) Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 compan
This live feed shows all institutional transactions in real time.
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)
SC 13D - Intersect ENT, Inc. (0001271214) (Subject)
SC 13G - Intersect ENT, Inc. (0001271214) (Subject)
Live finance-specific insights
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm
Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may